Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium

R. L. Adams, I. P. Adams, S. W. Lindow, W. Zhong, Stephen Atkin

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Angiogenesis is characterised by activation, migration and proliferation of endothelial cells and is central to the pathology of cancer cardiovascular disease and chronic inflammation. Somatostatin is an inhibitory polypeptide that acts through five receptors (sst 1, 2, 3, 4, 5). Sst has previously been reported in endothelium, but their role remains obscure. Here, we report the expression of sst in human umbilical vein endothelial cells (HUVECs) in vitro, during proliferation and quiescence. A protocol for culturing proliferating and quiescent HUVECs was established, and verified by analysing cell cycle distribution in propidium-iodide-stained samples using flow cytometry. Sst mRNA was then quantified in nine proliferating and quiescent HUVEC lines using quantitative reverse transcriptase-polymerase chain reaction. Sst 2 and 5 were preferentially expressed in proliferating HUVECs. All samples were negative for sst 4. Sst 1 and 3 expression and cell cycle progression were unrelated. Immunostaining for sst 2 and 5 showed positivity in proliferating but not quiescent cells, confirming sst 2 and 5 protein expression. Inhibition of proliferating cells with somatostatin analogues Octreotide and SOM230, which have sst 5 activity, was found (Octreotide 10-10-10-6M: 48.5-70.2% inhibition; SOM230 10-9-10-6 M: 44.9-65.4% inhibition) in a dose-dependent manner, suggesting that sst 5 may have functional activity in proliferation. Dynamic changes in sst 2 and 5 expression during the cell cycle and the inhibition of proliferation with specific analogues suggest that these receptors may have a role in angiogenesis.

Original languageEnglish
Pages (from-to)1493-1498
Number of pages6
JournalBritish Journal of Cancer
Volume92
Issue number8
DOIs
Publication statusPublished - 25 Apr 2005
Externally publishedYes

Fingerprint

Human Umbilical Vein Endothelial Cells
Endothelium
Cell Cycle
Octreotide
Somatostatin-Secreting Cells
Propidium
Somatostatin
Reverse Transcriptase Polymerase Chain Reaction
Flow Cytometry
Cardiovascular Diseases
Endothelial Cells
Pathology
Inflammation
Cell Line
Messenger RNA
Peptides
somatostatin receptor 5
somatostatin receptor 2
Neoplasms
Proteins

Keywords

  • Angiogenesis
  • Endothelium
  • Octreotide
  • Proliferation
  • SOM230
  • Somatostatin receptors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. / Adams, R. L.; Adams, I. P.; Lindow, S. W.; Zhong, W.; Atkin, Stephen.

In: British Journal of Cancer, Vol. 92, No. 8, 25.04.2005, p. 1493-1498.

Research output: Contribution to journalArticle

Adams, R. L. ; Adams, I. P. ; Lindow, S. W. ; Zhong, W. ; Atkin, Stephen. / Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. In: British Journal of Cancer. 2005 ; Vol. 92, No. 8. pp. 1493-1498.
@article{6cb3a7a6180b4763951351e41017b4d0,
title = "Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium",
abstract = "Angiogenesis is characterised by activation, migration and proliferation of endothelial cells and is central to the pathology of cancer cardiovascular disease and chronic inflammation. Somatostatin is an inhibitory polypeptide that acts through five receptors (sst 1, 2, 3, 4, 5). Sst has previously been reported in endothelium, but their role remains obscure. Here, we report the expression of sst in human umbilical vein endothelial cells (HUVECs) in vitro, during proliferation and quiescence. A protocol for culturing proliferating and quiescent HUVECs was established, and verified by analysing cell cycle distribution in propidium-iodide-stained samples using flow cytometry. Sst mRNA was then quantified in nine proliferating and quiescent HUVEC lines using quantitative reverse transcriptase-polymerase chain reaction. Sst 2 and 5 were preferentially expressed in proliferating HUVECs. All samples were negative for sst 4. Sst 1 and 3 expression and cell cycle progression were unrelated. Immunostaining for sst 2 and 5 showed positivity in proliferating but not quiescent cells, confirming sst 2 and 5 protein expression. Inhibition of proliferating cells with somatostatin analogues Octreotide and SOM230, which have sst 5 activity, was found (Octreotide 10-10-10-6M: 48.5-70.2{\%} inhibition; SOM230 10-9-10-6 M: 44.9-65.4{\%} inhibition) in a dose-dependent manner, suggesting that sst 5 may have functional activity in proliferation. Dynamic changes in sst 2 and 5 expression during the cell cycle and the inhibition of proliferation with specific analogues suggest that these receptors may have a role in angiogenesis.",
keywords = "Angiogenesis, Endothelium, Octreotide, Proliferation, SOM230, Somatostatin receptors",
author = "Adams, {R. L.} and Adams, {I. P.} and Lindow, {S. W.} and W. Zhong and Stephen Atkin",
year = "2005",
month = "4",
day = "25",
doi = "10.1038/sj.bjc.6602503",
language = "English",
volume = "92",
pages = "1493--1498",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium

AU - Adams, R. L.

AU - Adams, I. P.

AU - Lindow, S. W.

AU - Zhong, W.

AU - Atkin, Stephen

PY - 2005/4/25

Y1 - 2005/4/25

N2 - Angiogenesis is characterised by activation, migration and proliferation of endothelial cells and is central to the pathology of cancer cardiovascular disease and chronic inflammation. Somatostatin is an inhibitory polypeptide that acts through five receptors (sst 1, 2, 3, 4, 5). Sst has previously been reported in endothelium, but their role remains obscure. Here, we report the expression of sst in human umbilical vein endothelial cells (HUVECs) in vitro, during proliferation and quiescence. A protocol for culturing proliferating and quiescent HUVECs was established, and verified by analysing cell cycle distribution in propidium-iodide-stained samples using flow cytometry. Sst mRNA was then quantified in nine proliferating and quiescent HUVEC lines using quantitative reverse transcriptase-polymerase chain reaction. Sst 2 and 5 were preferentially expressed in proliferating HUVECs. All samples were negative for sst 4. Sst 1 and 3 expression and cell cycle progression were unrelated. Immunostaining for sst 2 and 5 showed positivity in proliferating but not quiescent cells, confirming sst 2 and 5 protein expression. Inhibition of proliferating cells with somatostatin analogues Octreotide and SOM230, which have sst 5 activity, was found (Octreotide 10-10-10-6M: 48.5-70.2% inhibition; SOM230 10-9-10-6 M: 44.9-65.4% inhibition) in a dose-dependent manner, suggesting that sst 5 may have functional activity in proliferation. Dynamic changes in sst 2 and 5 expression during the cell cycle and the inhibition of proliferation with specific analogues suggest that these receptors may have a role in angiogenesis.

AB - Angiogenesis is characterised by activation, migration and proliferation of endothelial cells and is central to the pathology of cancer cardiovascular disease and chronic inflammation. Somatostatin is an inhibitory polypeptide that acts through five receptors (sst 1, 2, 3, 4, 5). Sst has previously been reported in endothelium, but their role remains obscure. Here, we report the expression of sst in human umbilical vein endothelial cells (HUVECs) in vitro, during proliferation and quiescence. A protocol for culturing proliferating and quiescent HUVECs was established, and verified by analysing cell cycle distribution in propidium-iodide-stained samples using flow cytometry. Sst mRNA was then quantified in nine proliferating and quiescent HUVEC lines using quantitative reverse transcriptase-polymerase chain reaction. Sst 2 and 5 were preferentially expressed in proliferating HUVECs. All samples were negative for sst 4. Sst 1 and 3 expression and cell cycle progression were unrelated. Immunostaining for sst 2 and 5 showed positivity in proliferating but not quiescent cells, confirming sst 2 and 5 protein expression. Inhibition of proliferating cells with somatostatin analogues Octreotide and SOM230, which have sst 5 activity, was found (Octreotide 10-10-10-6M: 48.5-70.2% inhibition; SOM230 10-9-10-6 M: 44.9-65.4% inhibition) in a dose-dependent manner, suggesting that sst 5 may have functional activity in proliferation. Dynamic changes in sst 2 and 5 expression during the cell cycle and the inhibition of proliferation with specific analogues suggest that these receptors may have a role in angiogenesis.

KW - Angiogenesis

KW - Endothelium

KW - Octreotide

KW - Proliferation

KW - SOM230

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=18944381675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944381675&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602503

DO - 10.1038/sj.bjc.6602503

M3 - Article

VL - 92

SP - 1493

EP - 1498

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -